CD38 and Miyoshi myopathy: Several anti-CD38 mAbs have been developed and are under clinical development: Two fully human Abs (MOR202, TAK-079) and one chimeric (isatuximab); while DARA is the yet approved for the treatment of MM as single agent and in combination with standards of care in relapsed/refractory MM patients [40].